21. Reiss Y, Engelhardt B (1999) T cell interaction with ICAM-1-deficient endothelium in vitro: transendothelial migration of different T cell populations is mediated by endothelial ICAM-1 and ICAM-2. Int Immunol 11(9): 1527–1539. 22. Tanaka H, Yashiro M, Sunami T, Sakate Y, Kosaka K, et al. (2004) ICAM-2 gene therapy for peritoneal dissemination of a scirrhous gastric carcinoma. Clin Cancer Res 10: 4885–4892. 23. Melero I, Gabari I, Tirapu I, Arina A, Mazzolini G, et al. (2003) Anti-ICAM-2 monoclonal antibody synergizes with intratumor gene transfer of interleukim-12 inhibiting activation-induced T-cell death. Clin Cancer Res 9: 3546–3554. 24. Huang M-T, Larbi KY, Scheiermann C, Woodfin A, Gerwin N, et al. (2006) ICAM-2 mediates neutrophil transmigration in vivo: evidence for stimulus specificity and a role in PECAM-2-independent transmigration. Blood 107: 4721–4727. 25. Perez OD, Kinoshita S, Hitoshi Y, Payan DG, Kitamura T, et al. (2002) Activation of the PKB/AKT pathway by ICAM-2. Immunity 16: 51–65. 26. Singh K, Colmegna I, He X, Weyand CM, Goronzy JJ (2008) Synoviocyte stimulation by the LFA-1-intercellular adhesion molecule-2-ezrin-Akt pathway in rheumatoid arthritis. J Immunol 180(3): 1971–1978. 27. Huang M-T, Mason JC, Birdsey GM, Amsellem V, Gerwin N, et al. (2005) Endothelial intercellular adhesion molecule (ICAM)-2 regulates angiogenesis. Blood 106: 1636–1643. 28. Maris JM, Shusterman S (2006) Neuroblastoma. In: Holland JF, Frei III E, Kufe DW, Bast Jr RC, Hait WN, et al., eds. Cancer Medicine 7. Hamilton, Ontario: BC Decker, Inc. pp 1990–2012. 29. Yonemura S, Hirao M, Doi Y, Takahashi N, Kondo T, et al. (1998) Ezrin/ radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2. J Cell Biol 40: 885–895. 30. Heiska L, Kantor C, Parr T, Critchley DR, Vilja P, et al. (1999) Binding of the cytoplasmic domain of intercellular adhesion molecule-2 (ICAM-2) to a-actinin. J Biol Chem 271: 26214–26219. 31. Nortamo P, Salcedo R, Timonen T, Patarroyo M, Gahmberg CG (1991) A Monoclonal antibody to the human leukocyte adhesion molecule intercellular adhesion molecule-2. J Immunol 146: 2530–2535. 32. Kuhlman PA, Ellis J, Critchley DR, Bagshaw CR (1994) The kinetics of the interaction between the actin-binding domain of alpha-actinin and F-actin. FEBS Lett 339: 297–301. 33. Thompson J, Guichard SM, Cheshire PJ, Richmond LB, Poquette CA, et al. (2001) Development, characterization, and therapy of a disseminated model of childhood neuroblastoma in SCID mice. Cancer Chemother Pharmacol 47: 211–221. ICAM-2 Limits Metastasis 34. Simon T, Spitz R, Faldum A, Hero B, Berthold F (2004) New definition of low- risk neuroblastoma using stage, age, and 1p and MYCN status. J Pediatr Hematol Oncol 26: 791–796. 35. Schwab M, Shimada H, Joshi V, Brodeur GM (2000) Neuroblastic tumours of adrenal gland and sympathetic nervous system. In: Kleihues P, Cavenee WK, eds. Pathology and genetics of tumours of the nervous system. Lyon: World Health Organization, IARC Press. pp 153–161. 36. Chen CJ, Kirshner J, Sherman MA, Hu W, Hguyen T, et al. (2007) Mutation analysis of the short cytoplasmic domain of the cell-cell adhesion molecule CEACAM1 identifies residues that orchestrate actin binding and lumen formation. J Biol Chem 282: 5749–5760. 37. Izzi L, Turbide C, Houde C, Kunath T, Beauchemin N (1999) cis-Determinants in the cytoplasmic domain of CEACAM1 responsible for its tumor inhibitory function. Oncogene 18(40): 5563–5572. 38. Makitie T, Carpen O, Vaheri A, Kivela T (2001) Ezrin as a prognostic indicator and its relationship to tumor characteristics in uveal malignant melanoma. Investigative Ophthalmol & Visual Scient 42: 2442–2449. 39. Moilanen J, Lassus H, Leminen A, Vaheri A, Butzow R, et al. (2003) Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients. Gynecologic Oncol 90: 273–281. 40. Honda K, Yamada T, Hayashida Y, Idogawa M, Sato S, et al. (2005) Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer. Gastroenterology 128: 51–62. 41. Menez J, Chansac BLM, Dorothee G, Vergnon I, Jalil A, et al. (2004) Mutant alpha-actinin-4 promotes tumorigenicity and regulates cell motility of a human lung carcinoma. Oncogene 23: 2630–2639. 42. James MF, Beauchamp RL, Manchanda N, Kazlauskas A, Ramesh V (2004) A NHERF binding site links the bPDGFR to the cytoskeleton and regulates cell spreading and migration. J Cell Sci 117: 2951–2961. 43. Kobayashi H, Sagara J, Kurita H, Morifuji M, Ohishi M, et al. (2004) Clinical significance of cellular distribution of moesin in patients with oral squamous cell carcinoma. Clin Cancer Res 10: 572–580. 44. Kleinman HK, Jacob K (1998) Invasion assays. In: Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, et al., eds. Current Protocols in Cell Biology. John Wiley & Sons, Inc. Unit 12.2. 45. Pietersz GA, Li W, Apostolopoulos V (2001) A 16-mer peptide (RQI- KIWFQNRRMKWKK) from antennapedia preferentially targets the Class I pathway. Vaccine f19: 1397–1405. 46. Kuhlman PA, Hemmings L, Critchley DR (1992) The identification and characterization of an actin-binding site in a-actinin by mutagenesis. FEBS 304: 201–206. PLoS ONE | www.plosone.org 13 November 2008 | Volume 3 | Issue 11 | e3629